Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Nabilone

FDA-approved product (capsule, oral), marketed as Cesamet.

Registered studies
35
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Nabilone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Nausea
  • Nausea and vomiting
  • Post operative nausea and vomiting

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antiemetics
FDA pharmacologic class
Cannabinoid FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli29.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis37.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

35registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Nabilone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Nabilone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use Disorder

    NCT07644052 · start 2026-06-17

    Registered record
    Registry ID
    NCT07644052
    Conditions
    Cannabis Withdrawal
    Interventions
    PP-01; Nabilone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2026-06-17
    Completion
    2027-09
    Enrolment
    420

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCannabis Withdrawal
    InterventionPP-01; Nabilone; Placebo
    PhasePhase 3
    Registry statusRecruiting

  • Nabilone Use For Acute Pain in Inflammatory Bowel Disease Patients

    NCT03422861 · start 2023-12

    Registered record
    Registry ID
    NCT03422861
    Conditions
    Inflammatory Bowel Diseases
    Interventions
    Nabilone; Placebos
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-12
    Completion
    2024-12
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInflammatory Bowel Diseases
    InterventionNabilone; Placebos
    PhaseNot applicable
    Registry statusUnknown

  • Investigating the Effects of Nabilone on Endocannabinoid Metabolism

    NCT05885685 · start 2023-10-31

    Registered record
    Registry ID
    NCT05885685
    Conditions
    Healthy
    Interventions
    Nabilone Oral Capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2023-10-31
    Completion
    2025-12-05
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionNabilone Oral Capsule
    PhasePhase 4
    Registry statusCompleted

  • Nabilone for Agitation in Frontotemporal Dementia

    NCT05742698 · start 2023-03-07

    Registered record
    Registry ID
    NCT05742698
    Conditions
    Frontotemporal Dementia; Frontotemporal Dementia, Behavioral Variant; Primary Progressive Aphasia; bvFTD; PPA; FTD
    Interventions
    Nabilone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2023-03-07
    Completion
    2025-12-31
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFrontotemporal Dementia; Frontotemporal Dementia, Behavioral Variant; Primary Progressive Aphasia; bvFTD +2 more
    InterventionNabilone; Placebo
    PhasePhase 2
    Registry statusTerminated

  • Cannabinoids and an Anti-inflammatory Diet for the Treatment of Neuropathic Pain After Spinal Cord Injury

    NCT04057456 · start 2023-03-01

    Registered record
    Registry ID
    NCT04057456
    Conditions
    Spinal Cord Injuries; Neuropathic Pain
    Interventions
    Placebo diet; Anti-inflammatory diet; Nabilone Capsules; Placebo capsules
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2023-03-01
    Completion
    2024-12-01
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpinal Cord Injuries; Neuropathic Pain
    InterventionPlacebo diet; Anti-inflammatory diet; Nabilone Capsules; Placebo capsules
    PhasePhase 3
    Registry statusCompleted

  • Effect of PP-01 on Cannabis Withdrawal Syndrome

    NCT05494437 · start 2022-10-27

    Registered record
    Registry ID
    NCT05494437
    Conditions
    Cannabis Withdrawal
    Interventions
    PP-01 High Dose; PP-01 Low Dose; Placebo; Nabilone; Gabapentin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-10-27
    Completion
    2023-08-21
    Enrolment
    234

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCannabis Withdrawal
    InterventionPP-01 High Dose; PP-01 Low Dose; Placebo; Nabilone +1 more
    PhasePhase 2
    Registry statusCompleted

  • DIalysis Symptom COntrol-Pruritus Outcome Trial

    NCT05180968 · start 2022-08-02

    Registered record
    Registry ID
    NCT05180968
    Conditions
    End Stage Renal Disease; Pruritus
    Interventions
    Nabilone 0.5 MG Oral Capsule; Placebo Nabilone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2022-08-02
    Completion
    2023-08-11
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEnd Stage Renal Disease; Pruritus
    InterventionNabilone 0.5 MG Oral Capsule; Placebo Nabilone
    PhasePhase 3
    Registry statusCompleted

  • Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities

    NCT05273320 · start 2022-03-17

    Registered record
    Registry ID
    NCT05273320
    Conditions
    Intellectual Disability; Developmental Disability; Aggression; Behavior Problem
    Interventions
    Nabilone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-03-17
    Completion
    2025-08-14
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntellectual Disability; Developmental Disability; Aggression; Behavior Problem
    InterventionNabilone
    PhasePhase 1
    Registry statusCompleted

  • Multimodal Assessment of Cannabinoid Target Engagement in Adults With Obsessive-Compulsive Disorder

    NCT04880278 · start 2022-03-01

    Registered record
    Registry ID
    NCT04880278
    Conditions
    Obsessive-Compulsive Disorder
    Interventions
    Nabilone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    2022-03-01
    Completion
    2024-05-08
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObsessive-Compulsive Disorder
    InterventionNabilone; Placebo
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn

  • A Pilot Trial of Nabilone for the Treatment of Obesity

    NCT04801641 · start 2021-09-17

    Registered record
    Registry ID
    NCT04801641
    Conditions
    Obesity
    Interventions
    Placebo; Nabilone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2021-09-17
    Completion
    2023-08-14
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObesity
    InterventionPlacebo; Nabilone
    PhasePhase 2
    Registry statusTerminated

  • Adjunctive CB1 Agonist Nabilone in Inpatients With Active Suicidal Ideation

    NCT04807829 · start 2021-04

    Registered record
    Registry ID
    NCT04807829
    Conditions
    Suicidal Ideation
    Interventions
    Nabilone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2021-04
    Completion
    2022-04
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSuicidal Ideation
    InterventionNabilone; Placebo
    PhasePhase 2
    Registry statusWithdrawn

  • Nabilone for Agitation Blinded Intervention Trial

    NCT04516057 · start 2021-02-01

    Registered record
    Registry ID
    NCT04516057
    Conditions
    Alzheimer Disease; Agitation
    Interventions
    Nabilone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2021-02-01
    Completion
    2027-04
    Enrolment
    112

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease; Agitation
    InterventionNabilone; Placebo
    PhasePhase 3
    Registry statusRecruiting

  • Nabilone for Non-motor Symptoms in Parkinson's Disease

    NCT03773796 · start 2018-08-06

    Registered record
    Registry ID
    NCT03773796
    Conditions
    Parkinson Disease
    Interventions
    Nabilone 0.25 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-08-06
    Completion
    2020-01-31
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionNabilone 0.25 mg
    PhasePhase 3
    Registry statusCompleted

  • Nabilone for Non-motor Symptoms in Parkinson's Disease

    NCT03769896 · start 2017-10-03

    Registered record
    Registry ID
    NCT03769896
    Conditions
    Parkinson Disease
    Interventions
    Nabilone 0.25 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-10-03
    Completion
    2019-07-15
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionNabilone 0.25 mg; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Cannabinoid Medication for Adults With OCD

    NCT02911324 · start 2016-09

    Registered record
    Registry ID
    NCT02911324
    Conditions
    Obsessive-Compulsive Disorder
    Interventions
    Nabilone; Exposure and Response Prevention Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2016-09
    Completion
    2019-01
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObsessive-Compulsive Disorder
    InterventionNabilone; Exposure and Response Prevention Therapy
    PhasePhase 1 / Phase 2
    Registry statusCompleted